US › Healthcare

Palisade Bio Inc (PALI)

US · Healthcare · Biotechnology

$1.41-8.44%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$500,000

Net profit

$-10.6M

EPS

$-0.05

EPS estimate

$-0.05

Net margin

-2,114.8%

EPS came in at -0.05 against a street estimate of -0.05 — a beat of 0.0%.

Key statistics

Market cap

$252.7M

P/E

2.4

Forward P/E

0.0

P/B

2.31

Book value

$0.70

EPS (TTM)

$0.60

52-week high

$2.86

52-week low

$1.32

50-day MA

$1.88

200-day MA

$1.91

Beta

1.62

Analyst view

Analysts rate Palisade Bio Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $10.22.

Shareholding

Insiders

4.16%

Institutions

101.35%

Largest institutional holders

Fund	Stake
Soleus Capital Management, L.P.	7.50%
Ameriprise Financial Inc	6.60%
B Group, Inc	6.55%
HHG PLC	6.13%
Jupiter Topco LLC	6.13%
BlackRock Inc	5.99%
Octagon Capital Advisors LP	5.90%
Perceptive Advisors LLC	4.83%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Palisade Bio Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.